Hydrogen Activates ATP-Binding Cassette Transporter A1-Dependent Efflux Ex Vivo and Improves High-Density Lipoprotein Function in Patients With Hypercholesterolemia: A Double-Blinded, Randomized, and Placebo-Controlled Trial.
Guohua Song, Quanqiang Lin, Hui Zhao, Meiyuan Liu, Fenglong Ye, Yujuan Sun, Yang Yu, Shoudong Guo, Peng Jiao, Yun Wu, Guoyong Ding, Qiang Xiao, Shucun Qin · The Journal of clinical endocrinology and metabolism · 2015
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 9 patients with hypercholesterolemia and their underlying mechanisms in a double-blinded, H₂ treatment increased the effective rate in down-regulating plasma levels of total cholesterol (47.06% vs 17.65%) and LDL cholesterol (47.06% vs 23.53%). These findings add human evidence supporting molecular hydrogen's therapeutic potential for metabolic syndrome.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in 9 patients with hypercholesterolemia and their underlying mechanisms in a double-blinded. H₂ treatment increased the effective rate in down-regulating plasma levels of total cholesterol (47.06% vs 17.65%) and LDL cholesterol (47.06% vs 23.53%).
What the Researchers Studied
The researchers studied 9 patients with hypercholesterolemia and their underlying mechanisms in a double-blinded. The study used a randomized, double-blind, placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 10 weeks. H₂ treatment increased the effective rate in down-regulating plasma levels of total cholesterol (47.06% vs 17.65%) and LDL cholesterol (47.06% vs 23.53%).
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for metabolic syndrome and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind, placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 9 patients with hypercholesterolemia and their underlying mechanisms in a double-blinded. The reported sample size was 68. The study used a randomized, double-blind, placebo-controlled human clinical trial. The hydrogen delivery method was hydrogen-rich water. The reported treatment duration was 10 weeks.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.